Maria K. Haanpää
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria K. Haanpää has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- James M. Ford
Department of Genetics, Stanford School of Medicine, Stanford, USA
15 shared publications Joshua J. Gruber
15 shared publications- Justin Chen
Omega Therapeutics, Inc., Cambridge, USA
15 shared publications Natalie Jäger
15 shared publicationsMichael P. Snyder
14 shared publications- Bobby George Ng
Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2026 (1)
Next‐Generation Genetic Testing in the Diagnostics of Neurological Disease in Southwest Finland in 2010–2021: A Register‐Based Study
Neurological disorders are heterogeneous and sometimes challenging to diagnose. Next‐generation sequencing (NGS) panels and exome sequencing methods are increasingly advocated as first‐tier genetic investigations. In this retrospective, single‐centre, register‐based study, we investigated the use of NGS‐based investigations in the diagnostics of adult neurological disease at Turku University Hospital (TUH) (Turku, Finland) during 2010–2021. We identified patients who underwent any genetic testing to investigate neurologic disease in 2010–2021. NGS gene panel studies and exome investigations were scrutinised further. Data were collected from the TUH electronic medical records. We identified N = 844 patients (347 men and 497 women) who fulfilled the initial inclusion criteria. In this group, 331 NGS panels and 99 exome analyses were performed. The median age at the time of the first included genetic test was 45 years (range: 16–96 years). The diagnostic rate was 19% for all NGS‐based studies. Amongst different patient groups, the diagnostic yield was highest in developmental and intellectual disorders (39%), second highest in neuromuscular disorders (38%) and lower in epilepsy and ataxia (13% and 10%, respectively). Amongst neurological disorders, the diagnostic yield of genetic testing differs between different patient phenotypes and based on the genetic testing selection. Further studies are needed to determine optimal strategies, with the highest yield and lowest cost, for genetic investigations in neurological disorders.
- 1 January 2026
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 2026 (1)
Open AccessNext‐Generation Genetic Testing in the Diagnostics of Neurological Disease in Southwest Finland in 2010–2021: A Register‐Based Study
Neurological disorders are heterogeneous and sometimes challenging to diagnose. Next‐generation sequencing (NGS) panels and exome sequencing methods are increasingly advocated as first‐tier genetic investigations. In this retrospective, single‐centre, register‐based study, we investigated the use of NGS‐based investigations in the diagnostics of adult neurological disease at Turku University Hospital (TUH) (Turku, Finland) during 2010–2021. We identified patients who underwent any genetic testing to investigate neurologic disease in 2010–2021. NGS gene panel studies and exome investigations were scrutinised further. Data were collected from the TUH electronic medical records. We identified N = 844 patients (347 men and 497 women) who fulfilled the initial inclusion criteria. In this group, 331 NGS panels and 99 exome analyses were performed. The median age at the time of the first included genetic test was 45 years (range: 16–96 years). The diagnostic rate was 19% for all NGS‐based studies. Amongst different patient groups, the diagnostic yield was highest in developmental and intellectual disorders (39%), second highest in neuromuscular disorders (38%) and lower in epilepsy and ataxia (13% and 10%, respectively). Amongst neurological disorders, the diagnostic yield of genetic testing differs between different patient phenotypes and based on the genetic testing selection. Further studies are needed to determine optimal strategies, with the highest yield and lowest cost, for genetic investigations in neurological disorders.
- Open Access
The Nordic ChiCaP Network: An interdisciplinary approach to childhood cancer predisposition
- Open Access
- 11 June 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 170, 49-57
Attenuated Clinical Forms of Tubulinopathies in Children and Adults: A Series of 24 Individuals
- 11 June 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 170, 49-57
Open AccessAttenuated Clinical Forms of Tubulinopathies in Children and Adults: A Series of 24 Individuals
- Open Access
- 22 May 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (7) , 858-863
Comparison of the ABC and ACMG systems for variant classification
The ABC and ACMG variant classification systems were compared by asking mainly European clinical laboratories to classify variants in 10 challenging cases using both systems, and to state if the variant in question would be reported as a relevant result or not as a measure of clinical utility. In contrast to the ABC system, the ACMG system was not made to guide variant reporting but to determine the likelihood of pathogenicity. Nevertheless, this comparison is justified since the ACMG class determines variant reporting in many laboratories. Forty-three laboratories participated in the survey. In seven cases, the classification system used did not influence the reporting likelihood when variants labeled as “maybe report” after ACMG-based classification were included. In three cases of population frequent but disease-associated variants, there was a difference in favor of reporting after ABC classification. A possible reason is that ABC step C (standard variant comments) allows a variant to be reported in one clinical setting but not another, e.g., based on Bayesian-based likelihood calculation of clinical relevance. Finally, the selection of ACMG criteria was compared between 36 laboratories. When excluding criteria used by less than four laboratories (<10%), the average concordance rate was 46%. Taken together, ABC-based classification is more clear-cut than ACMG-based classification since molecular and clinical information is handled separately, and variant reporting can be adapted to the clinical question and phenotype. Furthermore, variants do not get a clinically inappropriate label, like pathogenic when not pathogenic in a clinical context, or variant of unknown significance when the significance is known.
- 22 May 2024
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 32 (7) , 858-863
Open AccessComparison of the ABC and ACMG systems for variant classification
The ABC and ACMG variant classification systems were compared by asking mainly European clinical laboratories to classify variants in 10 challenging cases using both systems, and to state if the variant in question would be reported as a relevant result or not as a measure of clinical utility. In contrast to the ABC system, the ACMG system was not made to guide variant reporting but to determine the likelihood of pathogenicity. Nevertheless, this comparison is justified since the ACMG class determines variant reporting in many laboratories. Forty-three laboratories participated in the survey. In seven cases, the classification system used did not influence the reporting likelihood when variants labeled as “maybe report” after ACMG-based classification were included. In three cases of population frequent but disease-associated variants, there was a difference in favor of reporting after ABC classification. A possible reason is that ABC step C (standard variant comments) allows a variant to be reported in one clinical setting but not another, e.g., based on Bayesian-based likelihood calculation of clinical relevance. Finally, the selection of ACMG criteria was compared between 36 laboratories. When excluding criteria used by less than four laboratories (<10%), the average concordance rate was 46%. Taken together, ABC-based classification is more clear-cut than ACMG-based classification since molecular and clinical information is handled separately, and variant reporting can be adapted to the clinical question and phenotype. Furthermore, variants do not get a clinically inappropriate label, like pathogenic when not pathogenic in a clinical context, or variant of unknown significance when the significance is known.
- Open Access
- 4 December 2023
- Published by S. Karger AG in Molecular Syndromology
- Vol. 15 (2) , 149-155
Report of a Novel Homozygous Intragenic DCC Duplication and a Review of Literature of Developmental Split-Brain Syndrome aka Horizontal Gaze Palsy with Progressive Scoliosis-2 with Impaired Intellectual Development Syndrome
Introduction: Horizontal gaze palsy with progressive scoliosis-2 (HGPPS2, MIM 617542) with impaired intellectual development aka developmental split-brain syndrome is an ultra-rare congenital disorder caused by pathogenic biallelic variants in the deleted in colorectal cancer (DCC) gene. Case Presentation: We report the clinical and genetic characterization of a Syrian patient with a HGPPS2 phenotype and review the previously published cases of HGPPS2. The genetic screening was performed using exome sequencing on Illumina platform. Genetic analysis revealed a novel DCC c.(?_1912)_(2359_?)dup, p.(Ser788Tyrfs*4) variant segregating recessively in the family. This type of variant has not been described previously in the HGPPS2 patients. To date, including the case reported here, three different homozygous pathogenic frameshift variants, one homozygous missense variant, and an intragenic duplication in the DCC gene have been reported in 8 patients with the HGPPS2 syndrome. Conclusion: The analysis of duplications and deletions in the DCC should be included in the routine genetic diagnostic evaluation of patients with suspected HGPPS2. This report expands the knowledge of phenotypic and genotypic spectrum of pathogenic variants causing HGPPS2.
- 4 December 2023
- Published by S. Karger AG in Molecular Syndromology
- Vol. 15 (2) , 149-155
Open AccessReport of a Novel Homozygous Intragenic DCC Duplication and a Review of Literature of Developmental Split-Brain Syndrome aka Horizontal Gaze Palsy with Progressive Scoliosis-2 with Impaired Intellectual Development Syndrome
Introduction: Horizontal gaze palsy with progressive scoliosis-2 (HGPPS2, MIM 617542) with impaired intellectual development aka developmental split-brain syndrome is an ultra-rare congenital disorder caused by pathogenic biallelic variants in the deleted in colorectal cancer (DCC) gene. Case Presentation: We report the clinical and genetic characterization of a Syrian patient with a HGPPS2 phenotype and review the previously published cases of HGPPS2. The genetic screening was performed using exome sequencing on Illumina platform. Genetic analysis revealed a novel DCC c.(?_1912)_(2359_?)dup, p.(Ser788Tyrfs*4) variant segregating recessively in the family. This type of variant has not been described previously in the HGPPS2 patients. To date, including the case reported here, three different homozygous pathogenic frameshift variants, one homozygous missense variant, and an intragenic duplication in the DCC gene have been reported in 8 patients with the HGPPS2 syndrome. Conclusion: The analysis of duplications and deletions in the DCC should be included in the routine genetic diagnostic evaluation of patients with suspected HGPPS2. This report expands the knowledge of phenotypic and genotypic spectrum of pathogenic variants causing HGPPS2.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Purpose:Understanding and explaining hereditary predisposition to cancer has focused on the genetic etiology of the disease. However, mutations in known genes associated with breast cancer, such as BRCA1 and BRCA2, account for less than 25% of familial cases of breast cancer. Recently, specific epigenetic modifications at BRCA1 have been shown to promote hereditary breast cancer, but the broader potential for epigenetic contribution to hereditary breast cancer is not yet well understood.Experimental Design:We examined DNA methylation through deep bisulfite sequencing of CpG islands and known promoter or regulatory regions in peripheral blood DNA from 99 patients with familial or early-onset breast or ovarian cancer, 6 unaffected BRCA mutation carriers, and 49 unaffected controls.Results:In 9% of patients, we observed altered methylation in the promoter regions of genes known to be involved in cancer, including hypermethylation at the tumor suppressor PTEN and hypomethylation at the proto-oncogene TEX14. These alterations occur in the form of allelic methylation that span up to hundreds of base pairs in length.Conclusions:Our observations suggest a broader role for DNA methylation in early-onset, familial risk breast cancer. Further studies are warranted to clarify these mechanisms and the benefits of DNA methylation screening for early risk prediction of familial cancers.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Purpose:Understanding and explaining hereditary predisposition to cancer has focused on the genetic etiology of the disease. However, mutations in known genes associated with breast cancer, such as BRCA1 and BRCA2, account for less than 25% of familial cases of breast cancer. Recently, specific epigenetic modifications at BRCA1 have been shown to promote hereditary breast cancer, but the broader potential for epigenetic contribution to hereditary breast cancer is not yet well understood.Experimental Design:We examined DNA methylation through deep bisulfite sequencing of CpG islands and known promoter or regulatory regions in peripheral blood DNA from 99 patients with familial or early-onset breast or ovarian cancer, 6 unaffected BRCA mutation carriers, and 49 unaffected controls.Results:In 9% of patients, we observed altered methylation in the promoter regions of genes known to be involved in cancer, including hypermethylation at the tumor suppressor PTEN and hypomethylation at the proto-oncogene TEX14. These alterations occur in the form of allelic methylation that span up to hundreds of base pairs in length.Conclusions:Our observations suggest a broader role for DNA methylation in early-onset, familial risk breast cancer. Further studies are warranted to clarify these mechanisms and the benefits of DNA methylation screening for early risk prediction of familial cancers.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
List of regions identified as having potential allelic methylation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
List of regions identified as having potential allelic methylation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Figure S2. Bisulfite sequencing after target enrichment provides highly quantitative methylation data across the genome. A) Average read depth for all samples was 71X, with an estimated bisulfite conversion rate of 98.69% across all samples. B) Increased read depth per CpG provides greater quantitative reliability; we routinely observed over 3 million CpGs with at least 5 reads. C) Kernel density plots of each subgroup within the cohort (Affect Carriers, Affected Noncarriers, Healthy Controls, and Unaffected Carriers) showed little global variation. D) Principle Component Analysis of the most variant CpGs across the cohort (n=7,590) did not separate sample subgroups and was only able to capture 5.615% and 1.677% of the variance in principle components 1 and 2, respectively.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Figure S2. Bisulfite sequencing after target enrichment provides highly quantitative methylation data across the genome. A) Average read depth for all samples was 71X, with an estimated bisulfite conversion rate of 98.69% across all samples. B) Increased read depth per CpG provides greater quantitative reliability; we routinely observed over 3 million CpGs with at least 5 reads. C) Kernel density plots of each subgroup within the cohort (Affect Carriers, Affected Noncarriers, Healthy Controls, and Unaffected Carriers) showed little global variation. D) Principle Component Analysis of the most variant CpGs across the cohort (n=7,590) did not separate sample subgroups and was only able to capture 5.615% and 1.677% of the variance in principle components 1 and 2, respectively.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
List of regions identified as having potential allelic methylation
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
List of regions identified as having potential allelic methylation
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Figure S4. Individual CpG methylation ratios at genes with promoters identified to have statistically significant differences in methylation. Low coverage at the ends of target enrichment regions lead to noise that artificially affects average methylation at ABRAXAS1 (A), MSH2 (B), STK11 (C), and TP53 (D). The gene structures are displayed below the heatmaps at their appropriate locations. Thin grey rectangles indicate the UTRs and thick blue rectangles indicate CDS; introns are represented by dashed lines. Arrows indicate putative TSS starts and the direction of transcription.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Figure S4. Individual CpG methylation ratios at genes with promoters identified to have statistically significant differences in methylation. Low coverage at the ends of target enrichment regions lead to noise that artificially affects average methylation at ABRAXAS1 (A), MSH2 (B), STK11 (C), and TP53 (D). The gene structures are displayed below the heatmaps at their appropriate locations. Thin grey rectangles indicate the UTRs and thick blue rectangles indicate CDS; introns are represented by dashed lines. Arrows indicate putative TSS starts and the direction of transcription.